Apogee Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Julian Harrison from BTIG maintained a Buy rating on the stock and has a $137.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Julian Harrison has given his Buy rating due to a combination of factors tied to Apogee’s lead asset zumilokibart and its potential commercial positioning. He highlights that the Phase 1b asthma data not only exceeded internal expectations but also compared very favorably to prior IL‑13 inhibitors and other advanced biologics on a key biomarker, FeNO, which is strongly linked to asthma exacerbations. The robust and durable reductions in FeNO, together with encouraging trends in lung function and Type 2 inflammation markers, support a substantially higher probability of clinical and regulatory success in asthma than previously assumed. Safety and tolerability in the early trial, including the absence of conjunctivitis and serious treatment-related events, further strengthen confidence in the drug’s risk‑benefit profile.
Harrison also underscores the strategic importance of achieving dual labeling in asthma and atopic dermatitis, a combination that historically drives strong prescriber preference and underpins blockbuster assets such as Dupixent. Given that a significant portion of atopic dermatitis patients also suffer from asthma, he expects zumilokibart’s eventual asthma label to materially expand its commercial reach beyond dermatology into allergists’ and pulmonologists’ practices. In light of the superior biomarker performance, favorable safety signals, and the sizable dual‑indication opportunity, he raises the assumed probability of success for zumilokibart in asthma, which in turn increases his price target for Apogee Therapeutics. Taken together, these elements justify maintaining a positive view on the stock and support his Buy recommendation.
Harrison covers the Healthcare sector, focusing on stocks such as Cullinan Management, Apogee Therapeutics, and Akebia Therapeutics. According to TipRanks, Harrison has an average return of 31.2% and a 53.82% success rate on recommended stocks.
In another report released today, Citi also maintained a Buy rating on the stock with a $95.00 price target.